abstract |
The present invention relates to variant AAV capsid polypeptides, wherein the variant capsid polypeptides exhibit an enhanced neutralization profile, increased transduction and/or tropism in human liver tissue or hepatocyte cells ( i.e. , human hepatocyte cells), or both, as compared non-variant parent capsid polypeptides. |